Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/17701
DC FieldValueLanguage
dc.contributor.authorTosheska Trajkovska, Katerinaen_US
dc.contributor.authorKostovska, Irenaen_US
dc.contributor.authorBosilkova, Gordanaen_US
dc.date.accessioned2022-05-19T12:22:14Z-
dc.date.available2022-05-19T12:22:14Z-
dc.date.issued2017-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/17701-
dc.description.abstractBackground. It is well known that a standard lipid profile measures total cholesterol, triglycerides, and HDL cholesterol (HDL-c), while LDL cholesterol is estimated. Subtracting HDL-c from total cholesterol, we can measure the amount of cholesterol carried by all lipoproteins except HDL. This simple math will give the amount of non-HDL cholesterol (non-HDL-c) within all atherogenic lipoproteins. However, although it is so easy, biochemical laboratories rarely report the value of non-HDL-c. Aim of the study. The aim of our study is to highlight the results of several studies that clearly establish the clinical use of non–HDL cholesterol as a common predictor of blood lipid patterns associated with increased risk of heart disease. Material. Recent literary evidence and clinical studies. Results. The most important document regarding non-HDL-c was delivered by the National Cholesterol Education Program Adult Treatment Panel III, where non–HDL-c was highlighted as a key secondary goal of therapy in lipid treatment and lipoprotein management. Other studies suggest that non-HDL-c shows a better correlation with small dense LDL particles than do other lipid parameters, including LDL-c. The treatment goal for non-HDL-c is usually 30 mg/dL above the LDL-c treatment target. Conclusion. Knowing that non–HDL-c is superior to LDL-c for the prediction of cardiovascular events, it is very important for each clinical chemistry laboratory to report non–HDL-c as a part of routine lipid status, with no added expense. Doctors could use it for optimal prevention of atherosclerosis and cardiovascular disease.en_US
dc.language.isoen_USen_US
dc.publisherBioMed Central Ltd.en_US
dc.relation.ispartofEPMA Journalen_US
dc.subjectnon HDL cholesterolen_US
dc.subjectblood lipidsen_US
dc.subjectpredictoren_US
dc.subjectheart diseaseen_US
dc.subjectlaboratory reporten_US
dc.titleThe importance of routinely reporting non-HDL cholesterol by the clinical laboratoryen_US
dc.typeProceeding articleen_US
dc.relation.conferenceEPMA World Congress 2017, Maltaen_US
dc.identifier.doi10.1007/s13167-017-0108-4-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Conference papers
Files in This Item:
File Опис SizeFormat 
2017_Article_EPMAWorldCongress (1).pdf8.94 MBAdobe PDFView/Open
Прикажи едноставен запис

Page view(s)

87
checked on 3.5.2025

Download(s)

21
checked on 3.5.2025

Google ScholarTM

Проверете

Altmetric


Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.